We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women.
- Authors
Rosenberg, Lynn; Bethea, Traci N.; Viscidi, Emma; Chi-Chen Hong; Troester, Melissa A.; Bandera, Elisa V.; Haiman, Christopher A.; Kolonel, Laurence N.; Olshan, Andrew F.; Ambrosone, Christine B.; Palmer, Julie R.; Hong, Chi-Chen
- Abstract
<bold>Background: </bold>Use of estrogen with progestin (combination therapy) is associated with increased incidence of estrogen receptor-positive (ER+) breast cancer in observational studies and randomized trials among postmenopausal white women. Whether this is also the case among African American women is not established.<bold>Methods: </bold>Using data from the AMBER consortium collected from 1993 to 2013, we assessed use of estrogen alone and of combination therapy in relation to ER+ and ER-negative (ER-) breast cancer risk in postmenopausal African American women, based on 1132 ER+ case patients, 512 ER- case patients, and 6693 control patients. Odds ratios (ORs) and confidence intervals (CIs) were estimated using multinomial logistic regression with control for breast cancer risk factors.<bold>Results: </bold>Forty-seven percent of control patients had used estrogen alone, combination therapy, or both. The odds ratio for ER+ breast cancer associated with combination use, relative to never use of either estrogen alone or combination therapy, was 1.50 (95% CI = 1.25 to 1.79). The increase was greater for recent (OR = 1.55, 95% CI = 1.21 to 1.99) and long-term use (OR = 1.75, 95% CI = 1.13 to 2.73) and among nonobese women (OR = 1.91, 95% CI = 1.29 to 2.83). Breast cancer risk was increased regardless of the interval between onset of menopause and initiation of combination use (OR = 1.43, 95% CI = 1.11 to 1.85, for <5 year interval; OR = 1.78, 95% CI = 1.34 to 2.37, for ≥5 year interval). Combination use was not associated with risk of ER- breast cancer, and use of estrogen alone was not associated with risk of either ER+ or ER- breast cancer.<bold>Conclusion: </bold>Use of estrogen with progestin increases risk of ER+ breast cancer in African American women. A decrease in use would be expected to reduce the number of ER+ cancers.
- Subjects
UNITED States; POSTMENOPAUSE; HORMONES; BREAST cancer; AFRICAN American women; HORMONE receptor positive breast cancer; PROTEIN analysis; STATISTICS on Black people; BREAST tumors; ESTROGEN; PROGESTATIONAL hormones; RESEARCH funding; LOGISTIC regression analysis; RETROSPECTIVE studies; ODDS ratio
- Publication
JNCI: Journal of the National Cancer Institute, 2016, Vol 108, Issue 4, p1
- ISSN
0027-8874
- Publication type
journal article
- DOI
10.1093/jnci/djv361